Redhill Biopharma Ltd. RDHL
0.50
(0.02)
(3.85%)
as of 25 Sep
- Market cap
- $3.2M
- P/E
- 0.0×
Follow RDHL
| Older periods | Mar '23 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
294.00% | (181.89%) | 0.00% | 0.00% | |
| (4.22%) | 7.59% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(102.41%) | (858.65%) | 0.00% | 0.00% | |
Average Days of Receivables |
53.08 | 34.67 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.65) | (1.70) | 0.00 | 0.00 | |
Free Cash Flow |
(32.15) | (33.53) | (33.53) | (36.11) | |
Capital Expenditures |
— | (0.19) | (0.03) | (0.01) | |
Piotroski F-Score |
2.00 | 4.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(85.43%) | (152.19%) | (414.75%) | 2,604.16% | |
Accounts Receivable Turnover |
2.87 | 1.67 | 0.00 | 0.00 | |
Accounts Payable Turnover |
5.34 | 5.29 | 0.00 | 0.00 | |
Inventory Turnover |
2.67 | 2.38 | 0.00 | 0.00 | |
Average Days of Payables |
59.24 | 57.33 | 0.00 | 0.00 | |
Days of Inventory on Hand |
79.50 | 90.98 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
11.23% | 16.53% | — | — | |
Selling, General and Administrative Expense of Revenue |
115.54% | 144.88% | — | — | |
Share Based Compensation of Revenue |
7.45% | 12.25% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
6.75 | (4.33) | 0.00 | 0.00 | |
Depreciation/Fixed assets |
10.28 | 268.87 | 434.90 | 492.78 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
3.88 | 1.55 | — | — | |
Operating CF per Share |
(2.65) | (1.70) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(10.10%) | 25.20% | — | — |
Columns are period end dates